Does Medicare Cover Zepbound or Mounjaro? The $50 GLP-1 Bridge, Explained (2026–2027)

Yes, for weight management — since July 1, 2026, and only in one form. Through the Medicare GLP-1 Bridge, a CMS demonstration running through December 31, 2027, eligible Medicare Part D enrollees can fill the Zepbound KwikPen for a $50 monthly copay; the Zepbound single-dose vials and single-dose pens are not included. Before July 2026 the answer for weight loss alone was a flat no, and that statutory rule still governs everything outside the Bridge. For type 2 diabetes (Mounjaro) and obstructive sleep apnea (Zepbound), Part D coverage works the ordinary way and does not go through the Bridge. This guide covers the Bridge's eligibility rules, what it costs and what it does not count toward, the statutory exclusion it sits on top of, the savings-card lockout, and the cash routes when none of that applies. Policy information current as of August 28, 2026 — not insurance or medical advice; your plan documents and CMS are the authority.

The Medicare GLP-1 Bridge: Zepbound KwikPen for $50 a month

The Bridge is a short-term CMS demonstration that runs from July 1, 2026 through December 31, 2027 and operates outside the normal Part D benefit. Three products are in it: all forms of Wegovy, all forms of Foundayo (oral orforglipron), and only the KwikPen formulation of Zepbound — the multi-dose pen. If your prescription is for Zepbound vials or the single-dose pen, it is not a Bridge prescription; ask the prescriber to write the KwikPen. You pay a flat $50 copay to the pharmacy for a one-month supply. Two catches that matter for the math: the $50 does not count toward your Part D deductible or the $2,100 out-of-pocket cap for 2026, and it cannot be spread through the Medicare Prescription Payment Plan.

Who qualifies. You must be 18 or older, enrolled in Medicare Part D, and prescribed the drug to reduce and maintain weight loss alongside lifestyle changes. The clinical bar is a BMI of 35 or higher on its own; a BMI of 30 or higher with chronic kidney disease (stage 3a or worse), heart failure with preserved ejection fraction, or high blood pressure uncontrolled on two medications; or a BMI of 27 or higher with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. The prescriber submits a prior authorization to a central CMS processor (CMS targets a 72-hour turnaround); once approved, refills do not need a new one unless you switch drugs. If you are prescribed tirzepatide for type 2 diabetes, sleep apnea or MASH, you are routed to ordinary Part D coverage instead — the Bridge is for the weight-management indication only. Full criteria and the prescriber fact sheet are on [CMS's Medicare GLP-1 Bridge pages](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers).

What happens after 2027. The Bridge hands off to a longer demonstration (the BALANCE Model) that Part D plans join voluntarily, so continued coverage from 2028 depends on the plan you pick in open enrollment. Treat the $50 as a two-year window, not a permanent benefit.

The rule underneath the Bridge: Part D itself still cannot cover weight-loss drugs

The starting point is a decades-old statute. Medicare Part D is legally prohibited from covering drugs when they are used for weight loss — a coverage exclusion written into the law that created the Part D benefit. That single rule is why a drug as effective as Zepbound, FDA-approved for obesity, is not a covered Part D benefit for that purpose. It isn't a formulary choice your plan made; it's a federal statutory exclusion that applies across Medicare. So outside the Bridge, if you're seeking tirzepatide purely for weight management, the Part D answer is still no — and no appeal changes a statutory exclusion. The Bridge exists precisely because CMS had to build a demonstration around that statute rather than through it.

The indications that can flip the answer to yes

The exclusion is about the use, not the molecule — which is exactly why the indication matters so much:

Type 2 diabetes (Mounjaro). When tirzepatide is prescribed as Mounjaro for type 2 diabetes, it is being used for a covered medical condition, not weight loss — so Medicare Part D plans can and frequently do cover it, subject to the plan's formulary placement, prior authorization, and cost-sharing. Mounjaro's pivotal SURPASS diabetes trials and its glucose-lowering plus weight effects are well established, and diabetes is squarely within Part D's scope. This is the most common route by which Medicare beneficiaries get tirzepatide covered. If you'd rather work the coverage question through a clinic than a compounded-medication subscription, our Knownwell review covers a Medicare-participating, insurance-billing weight care practice built around exactly that.

Obstructive sleep apnea (Zepbound). This is the newer and more important wrinkle. In late 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, on the strength of the SURMOUNT-OSA trial, which showed tirzepatide substantially reduced sleep-apnea severity (the apnea-hypopnea index) compared with placebo¹. Because OSA is a covered medical condition rather than "weight loss," that approval created a path for Part D coverage of Zepbound for the OSA indication — and CMS has signaled that plans may cover Zepbound when prescribed for OSA in eligible patients. We cover this indication in depth in our guide to Zepbound for sleep apnea. The catch: you have to actually have qualifying OSA, with the documentation to support it; obesity alone does not unlock this door.

The savings-card lockout that pushes beneficiaries to cash

Here's the trap that catches many people newly on Medicare. Eli Lilly's manufacturer savings card — the discount that can bring commercially-insured patients' cost down to as little as $25/month — excludes anyone enrolled in a government program: Medicare, Medicaid, the VA and TRICARE are all ineligible. So a Medicare beneficiary whose plan won't cover Zepbound for weight loss also can't use the savings card to soften the blow. That double bind is the reason so many Medicare-age patients end up paying cash through the self-pay route described below. (For the commercial-insurance picture and the savings card mechanics, see our does insurance cover Zepbound guide.) One structural consequence: if you are paying cash anyway, a program that bundles the medication into a monthly subscription is buying you less than it appears, and a pay-per-visit route can make more sense — our Sesame Care review covers that marketplace model and where the platform subscription still applies to brand products.

The cash route — and the 2026 pricing shift

If Medicare won't cover your tirzepatide (the typical situation for a weight-loss indication), the practical fallback is Eli Lilly's LillyDirect self-pay program, which sells brand Zepbound single-dose vials at roughly $299–$449 per month depending on dose (prices in effect since December 1, 2025; a 28-day, 4-vial supply): about $299 for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 mg and higher. Because the savings-card lockout doesn't apply to a straight cash purchase, self-pay vials are the most common legitimate path for Medicare beneficiaries seeking the drug for weight management. Compounded telehealth programs are the other cash option people land on, and shipping coverage matters more here than it might seem, since Medicare beneficiaries are spread across every state — Gala Health ships to all fifty and keeps a brand-name path open, though its headline monthly figure is a yearly-plan rate rather than a month-to-month one.

Separately, 2026 has brought policy movement aimed at lowering GLP-1 cash prices through direct government-negotiated and direct-to-consumer arrangements (commonly discussed under the **TrumpRx banner), which have been reported to drive certain GLP-1 cash prices toward a much lower monthly figure for eligible buyers. These arrangements are evolving and the exact terms, eligible products and timing have shifted as they roll out — so treat any specific low headline number as something to verify at the point of purchase**, not a guaranteed Medicare benefit. The durable, checkable benchmark remains the LillyDirect self-pay vial pricing above. For the full cash-price landscape — list price, coupons, vials vs pens — see our Zepbound cost and savings guide, our ranking of every program by published monthly price and our Zepbound vials vs pens self-pay breakdown.

How to find out what YOUR plan does

Because the answer turns on indication and plan formulary, the fastest way to get a real answer is to ask three specific questions of your Part D plan (the number is on your card):

1. 1.Is Mounjaro covered for type 2 diabetes on this plan's formulary, and on what tier / with what prior authorization?
2. 2.Is Zepbound covered for obstructive sleep apnea, and what documentation does the prior authorization require?
3. 3.What is my cost-sharing at each tier, and does the drug fall under any deductible phase?

If you're being treated for weight loss alone, expect the answer to be no under the statutory exclusion — in which case the self-pay route is the realistic path. If you have diabetes or qualifying OSA, the answer can be yes, and the work shifts to clearing prior authorization with the right documentation.

Does the drug justify the effort? What the evidence says

Tirzepatide's results are why people fight this coverage maze at all. In the 72-week SURMOUNT-1 obesity trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo²; head-to-head against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%³. And it's a long-term medication: in SURMOUNT-4, people who stopped regained substantial weight while those who continued kept losing⁴, which is exactly why ongoing coverage (or an affordable ongoing cash price) matters so much. For the full benefit-and-risk picture see our tirzepatide evidence guide, and for vetted ways to access the drug, our best tirzepatide providers overview and best place to get Zepbound online roundup.

The honest bottom line

Does Medicare cover tirzepatide? For weight management, yes since July 1, 2026 — the Zepbound KwikPen for a $50 monthly copay through the Medicare GLP-1 Bridge, if you meet the BMI criteria, your prescriber files the prior authorization, and you accept that the $50 does not count toward your Part D deductible or cap; vials and single-dose pens are excluded, and the program ends December 31, 2027. Outside the Bridge, the statute still bars Part D from covering weight-loss drugs, and the savings card is off-limits to Medicare and every other government plan. For type 2 diabetes (Mounjaro), usually yes through ordinary Part D. For obstructive sleep apnea (Zepbound), increasingly yes since the 2024 OSA approval, with documentation. When none of that applies, the realistic path is LillyDirect self-pay vials at ~$299–$449/month.